Details of the Drug Reposition

General Information of This Drug (ID: DMAMTGI)

Drug Name
SD-101   DMAMTGI
Synonyms HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
Drug Type
Oligonucleotide

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatitis C virus infection DISQ0M8R 1E51.1 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Skin disease DISDW8R6 EA00-EM0Z Phase 2 [2]
------------------------------------------------------------------------------------
3 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 1/2 [3]
Melanoma DIS1RRCY 2C30 Phase 1/2 [3]
Squamous head and neck cell carcinom DIS0UVDG 2D60.0 Phase 1/2 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02384460) Study of Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02521870) A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.